TScan Therapeutics, Inc. (TCRX) Financials
TCRX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 272.1 million | 121.3 million |
2023-09-30 | 291.4 million | 122.4 million |
2023-06-30 | 316.9 million | 126.3 million |
2023-03-31 | 173.6 million | 95.6 million |
TCRX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -24.2 million | 1.5 million |
2023-09-30 | 6.6 million | 1.3 million |
2023-06-30 | -22.4 million | 1.2 million |
2023-03-31 | -24.4 million | 1.1 million |
TCRX Net Income
No data available :(
TCRX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 192.0 million | - | 62.4 million |
2023-09-30 | 155.2 million | - | 57.0 million |
2023-06-30 | 208.8 million | - | 58.0 million |
2023-03-31 | 95.6 million | - | 55.8 million |
TCRX Shares Outstanding
TCRX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 469000 | 22.4 million | 6.2 million | 1.3 million |
2023-09-30 | 1.4 million | 22.7 million | 5.9 million | - |
2023-06-30 | 420000 | 21.2 million | 6.5 million | - |
2023-03-31 | 838000 | 21.8 million | 7.8 million | - |
TCRX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 7.2 million | 1.3 million |
2023-09-30 | 3.9 million | 1.3 million |
2023-06-30 | 3.1 million | 1.3 million |
2023-03-31 | 6.8 million | 1.5 million |
TCRX
Price: $8.56
52 week price:
Earnings Per Share: -1.36 USD
P/E Ratio: -2.59
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 133500
Market Capitalization: 371.3 million
Average Dividend Frequency: 4